X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) is a Healthcare company (Biotechnology) with a market capitalization of $316M. The Maz Rating grades it against the other companies in its sector.
X4 Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.09, X4 Pharmaceuticals, Inc. trades at 18.3x sales and 2.8x book value. Over the last twelve months it generated about $17M of revenue and a net loss of $69M. It runs a gross margin of 81.6%, an operating margin of -474.0% and a net margin of -474.7%. It shows return on equity of -49.6%, return on invested capital of -37.0% and a free cash flow yield of -30.3%. On the balance sheet: a debt-to-equity ratio of 0.56 and a current ratio of 13.22. Over the past 52 weeks the share price ranged from $2.43 to $4.83, with a beta of 0.35.
X4 Pharmaceuticals, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 12 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, X4 Pharmaceuticals, Inc. (XFOR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 18.2% / 30% · (Cash+Inv) / Mkt Cap (36m) 44.3% / 30% · Interest income / Revenue 63.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 18.2% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 44.3% / 33% · Receivables / Mkt Cap (36m) 0.35% / 49% · Interest income / Revenue 63.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 18.2% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 44.3% / 33.33% · Receivables / Mkt Cap (24m) 0.35% / 33.33% · Interest income / Revenue 63.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 29.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 84.4% / 33.33% · Receivables / Avg Assets (4Q) 0.50% / 33.33% · Interest income / Revenue 63.3% / 5% | Fail |
| FTSE | Debt / Total Assets 33.2% / 33.33% · (Cash+ST Inv) / Total Assets 81.0% / 33.33% · (Cash+Recv) / Total Assets 81.6% / 33.33% · Interest income / Revenue 63.3% / 5% | Fail |
No. As of September 2026, X4 Pharmaceuticals, Inc. (XFOR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. X4 Pharmaceuticals, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 63.3% of each dividend: X4 Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.